| Literature DB >> 28419210 |
Daniel P Prestes1, Esther Arbona1, Alexandra Nevett-Fernandez1, Ann E Woolley1,2,3, Vincent T Ho1,2,3, Sophia Koo1,2,3, Lindsey R Baden1,2,3, John Koreth1,2,3, Sarah P Hammond1,2,3, Nicolas C Issa1,2,3, Francisco M Marty1,2,3.
Abstract
Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.Entities:
Keywords: acute lymphoblastic leukemia; chronic myelogenous leukemia; cytomegalovirus; dasatinib; hematopoietic cell transplantation
Mesh：
Substances：
Year: 2017 PMID： 28419210 DOI： 10.1093/cid/cix325
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079